share_log

Peeling Back The Layers: Exploring Marinus Pharma Through Analyst Insights

Benzinga ·  Mar 26 09:00

Throughout the last three months, 4 analysts have evaluated Marinus Pharma (NASDAQ:MRNS), offering a diverse set of opinions from bullish to bearish.

The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.

BullishSomewhat BullishIndifferentSomewhat BearishBearish
Total Ratings21100
Last 30D10000
1M Ago11100
2M Ago00000
3M Ago00000

Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $21.75, with a high estimate of $27.00 and a low estimate of $9.00. Observing a 141.67% increase, the current average has risen from the previous average price target of $9.00.

price target chart

Understanding Analyst Ratings: A Comprehensive Breakdown

The standing of Marinus Pharma among financial experts...

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment